Monitor the company's first earnings report as a public company for guidance on revenue trajectory and pipeline progress. The IPO provides a cash runway but no revenue or profitability metrics were disclosed in this filing.
Price Chart
Executive Summary
Hemab Therapeutics completed its IPO of 19,262,500 shares at $18.00/share, raising $346.7M in gross proceeds. Concurrently, the company adopted a restated certificate and bylaws with standard public-company governance provisions (classified board, supermajority voting, exclusive forum). This is a routine post-IPO administrative filing with no new financial data or operational updates.
Key Facts
- IPO closed on May 4, 2026, with 19,262,500 shares sold including full exercise of underwriter option
- IPO price: $18.00 per share
- Gross proceeds: $346.7 million before underwriting discounts and expenses
- Restated certificate increases authorized common stock to 400,000,000 shares and authorizes 5,000,000 shares of undesignated preferred stock
- New governance features: classified board, director removal only for cause with 75% supermajority vote, no stockholder action by written consent, exclusive forum provisions
Financial Impact
IPO raised $346.7 million in gross proceeds; net proceeds will be lower after underwriting discounts and expenses (not specified)
Risk Factors
- Pre-revenue biotech with no approved products or disclosed financial performance
- Governance changes (classified board, supermajority requirements) reduce stockholder influence and could deter activist investors
- Potential dilution from authorized but unissued preferred stock
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-203988 |
| Document: d149100dex31.htm | 0001193125-26-203988 |
| Document: d149100d8k.htm | 0001193125-26-203988 |
| Document: 0001193125-26-203988-index-headers.html | 0001193125-26-203988 |
| Document: 0001193125-26-203988-index.html | 0001193125-26-203988 |
| Document: 0001193125-26-203988.txt | 0001193125-26-203988 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access